19-碘胆固醇 | 37414-03-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 19-碘胆固醇
• 中文别名: 19-碘胆固醇,95
• 英文名称: 19-iodo-5-cholesten-3β-ol
• 英文别名: 6β-Jodmethyl-19-nor-cholest-5(10)-en-3β-ol；19-iodocholesterol；19-iodo-cholest-5-en-3β-ol；Iodocholesterol；(3S,8S,9S,10S,13R,14S,17R)-10-(iodomethyl)-13-methyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 37414-03-2
• 化学式: C₂₇H₄₅IO
• 分子量: 512.558
• InChiKey: FIOAEFCJGZJUPW-FTLVODPJSA-N

物化性质

• 熔点：
  116-117℃

计算性质

• 辛醇/水分配系数(LogP)：
  9.3
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S22,S24/25

反应信息

• 作为反应物：
  描述：

  19-碘胆固醇 以 异丙醇 为溶剂， 生成 阿多甾醇
  参考文献：
  名称：

  Homoallylic rearrangement of 19-iodocholest-5-en-3β-ol: New adrenal scanning agent

  摘要：

  DOI：

  10.1016/s0039-128x(75)80025-0
• 作为产物：
  描述：

  cholest-5-en-3β,19-diol 19-toluene-p-sulfonate 在 sodium iodide 作用下， 生成 19-碘胆固醇
  参考文献：
  名称：

  Synthesis of a new adrenal cortex imaging agent 6β-131 I-iodomethyl-19-nor cholest -5(10)-en-3β-ol (NP-59)

  摘要：

  一种新的肾上腺皮质成像剂。6β-131 I-碘甲基-19-去甲胆甾-5(10)-烯-3β-醇（NP-59）[I]是通过19-碘胆固醇的同烯基重排或通过碘离子作为亲核试剂与Na131I进行后续交换，直接由胆甾-5-烯-3β,19-二醇-19-甲苯-对磺酸酯的同烯基重排合成的。NP-59在大鼠肾上腺中的浓度似乎比19-碘胆固醇高5倍，目前正在评估其作为人类诊断试剂的可能性。

  DOI：

  10.1002/jlcr.2590110318

文献信息

• [EN] FOSFLUCONAZOLE DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS<br/>[FR] DÉRIVÉS DE FOSFLUCONAZOLE, SYNTHÈSE, ET UTILISATION DANS DES FORMULATIONS À LONGUE DURÉE D'ACTION
  申请人：SEPS PHARMA N V

  公开号：WO2010105910A1

  公开（公告）日：2010-09-23

  The invention relates to a compound of formula (I) and the salts, N-oxides, quaternary amines, and stereoisomers thereof, wherein R1 to R8 are as defined in the claims. The invention further relates to intermediates and methods for the preparation of the compounds of formula (I). The invention also relates to the compounds of formula (I) for use as a medicament, particularly for the prevention or treatment of fungal infections.

  该发明涉及公式(I)的化合物及其盐、N-氧化物、季铵盐和立体异构体，其中R1至R8如权利要求中所定义。该发明进一步涉及用于制备公式(I)化合物的前体和方法。该发明还涉及公式(I)的化合物，用于作为药物，特别是用于预防或治疗真菌感染。
• Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations
  申请人：Gonnissen Yves

  公开号：US20120172336A2

  公开（公告）日：2012-07-05

  The invention relates to a compound of formula (1) and the salts, N-oxides, quaternary amines, and stereoisomers thereof, wherein R 1 to R 2 are as defined in the claims. The invention further relates to intermediates and methods for the preparation of the compounds of formula (I). The invention also relates to the compounds of formula (I) for use as a medicament, particularly for the prevention or treatment of fungal infections.

  本发明涉及一种式(1)的化合物及其盐、N-氧化物、季铵盐和立体异构体，其中R1到R2如权利要求中所定义。本发明还涉及制备式(I)化合物的中间体和方法。本发明还涉及用作药物的式(I)化合物，特别是用于预防或治疗真菌感染。
• 3-ethyl and 3-methyl ethers of 19-iodocholesterol as potential adrenal scanning agents
  作者：J.A. Owoyale、S.S. Szinai

  DOI：10.1016/s0039-128x(81)80013-x

  日期：1981.2

  as an adrenal scanning agent, was found to be unstable. However, the substitution of methoxyl and ethoxyl groups for the hydroxyl group in the 3 position rendered these derivatives much more stable in solid form than the parent compound. They showed concentration in the adrenals of dogs similar to that of 19-iodocholesterol itself and therefore may be useful as adrenal scanning agents.

  19-Iodocholesterol-131I 虽然可用作肾上腺扫描剂，但被发现不稳定。然而，甲氧基和乙氧基取代 3 位羟基使这些衍生物在固体形式下比母体化合物稳定得多。它们在狗的肾上腺中的浓度与 19-碘胆固醇本身的浓度相似，因此可用作肾上腺扫描剂。
• Halogen treatment of heart attack and ischemic injury
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10201570B2

  公开（公告）日：2019-02-12

  The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.

  本发明涉及卤素化合物（包括碘化物）和卤代化合物（包括碘化物、硫化物和硒）在治疗和预防疾病和伤害方面的用途。本发明进一步涉及包含卤素化合物和/或卤化金属化合物的组合物，包括药物组合物，以及制造此类化合物和向需要的受试者施用此类组合物的方法。
• Method of forming subtraction images
  申请人：Arakawa Satoshi

  公开号：US20050195943A1

  公开（公告）日：2005-09-08

  A radiation image signal is acquired from a radiation image of an object before being injected with a contrast medium, and a radiation image signal is acquired from a radiation image of the same object after being injected with the contrast medium. A subtraction process for subtracting image signal components of a plurality of the thus acquired radiation image signals, which image signal components represent corresponding pixels in the radiation images represented by the plurality of the radiation image signals, from one another is performed. A contrasted radiation image, in which a pattern of a specific structure of the object having been contrasted with the contrast medium in the radiation image has been extracted or enhanced, is thus formed. The contrast medium is a liposome, which contains a hydrophobic iodine compound as a film forming constituent.

  在注入造影剂之前，从物体的辐射图像中获取辐射图像信号，在注入造影剂之后，从同一物体的辐射图像中获取辐射图像信号。执行一个减法过程，将由此获取的多个辐射图像信号的图像信号分量相互减去，这些图像信号分量代表多个辐射图像信号所代表的辐射图像中的相应像素。这样就形成了对比辐射图像，其中提取或增强了辐射图像中被对比介质对比的物体的特定结构的图案。对比介质是一种脂质体，它含有一种疏水性碘化合物作为成膜成分。